NAV

Aclarubicin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Aclarubicin
DrugBank Accession Number
DB11617
Background

Not Available

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 811.878
Monoisotopic: 811.341520011
Chemical Formula
C42H53NO15
Synonyms
  • Aclacinomycin A
  • Aclarubicin
  • aclarubicina
External IDs
  • NSC-208734

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AmbroxolThe risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Bupivacaine.
ButacaineThe risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Butacaine.
ButambenThe risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Butamben.
CapsaicinThe risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Capsaicin.
ChloroprocaineThe risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Chloroprocaine.
CinchocaineThe risk or severity of methemoglobinemia can be increased when Aclarubicin is combined with Cinchocaine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Aclarubicin hydrochloride501948RI6675443-99-1KUSMIBXCRZTVML-PCCPLWKKSA-N

Categories

ATC Codes
L01DB04 — Aclarubicin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as anthracyclines. These are polyketides containing a tetracenequinone ring structure with a sugar attached by glycosidic linkage.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Anthracyclines
Sub Class
Not Available
Direct Parent
Anthracyclines
Alternative Parents
Tetracenequinones / Aminoglycosides / Anthracenecarboxylic acids / Anthraquinones / Naphthalenecarboxylic acids and derivatives / Disaccharides / O-glycosyl compounds / Tetralins / Aryl ketones / 1-hydroxy-2-unsubstituted benzenoids
show 16 more
Substituents
1,4-anthraquinone / 1-hydroxy-2-unsubstituted benzenoid / 1-hydroxy-4-unsubstituted benzenoid / 1-naphthalenecarboxylic acid or derivatives / 9,10-anthraquinone / Acetal / Alcohol / Amine / Amino acid or derivatives / Amino saccharide
show 37 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
phenols, trisaccharide derivative, methyl ester, polyketide, aminoglycoside, anthracycline, tetracenequinones (CHEBI:74619)
Affected organisms
Not Available

Chemical Identifiers

UNII
74KXF8I502
CAS number
57576-44-0
InChI Key
USZYSDMBJDPRIF-SVEJIMAYSA-N
InChI
InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1
IUPAC Name
methyl (1R,2R,4S)-4-{[(2R,4S,5S,6S)-4-(dimethylamino)-5-{[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-{[(2R,6S)-6-methyl-5-oxooxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate
SMILES
CC[C@@]1(O)C[C@H](O[C@H]2C[C@@H]([C@H](O[C@H]3C[C@H](O)[C@H](O[C@H]4CCC(=O)[C@H](C)O4)[C@H](C)O3)[C@H](C)O2)N(C)C)C2=C(O)C3=C(C=C2[C@H]1C(=O)OC)C(=O)C1=C(C(O)=CC=C1)C3=O

References

General References
  1. Jensen PB, Jensen PS, Demant EJ, Friche E, Sorensen BS, Sehested M, Wassermann K, Vindelov L, Westergaard O, Hansen HH: Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. Cancer Res. 1991 Oct 1;51(19):5093-9. [Article]
  2. Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O, Janssen J, Huijgens P, Zwart W, Neefjes J: Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun. 2013;4:1908. doi: 10.1038/ncomms2921. [Article]
  3. Pang B, de Jong J, Qiao X, Wessels LF, Neefjes J: Chemical profiling of the genome with anti-cancer drugs defines target specificities. Nat Chem Biol. 2015 Jul;11(7):472-80. doi: 10.1038/nchembio.1811. Epub 2015 May 11. [Article]
KEGG Drug
D02756
KEGG Compound
C18638
PubChem Compound
451415
PubChem Substance
347828010
ChemSpider
397638
BindingDB
50368351
RxNav
239
ChEBI
74619
ChEMBL
CHEMBL502620
ZINC
ZINC000085537142
Wikipedia
Aclarubicin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentAcute Myeloid Leukemia3
3Unknown StatusTreatmentAcute Myeloid Leukemia / Induction chemotherapy1
2Not Yet RecruitingTreatmentAcute Myeloid Leukemia / Elderly Patients / Newly Diagnosed1
2Unknown StatusTreatmentAcute Myeloid Leukemia1
2Unknown StatusTreatmentAcute Myeloid Leukemia / Relapsed Leukemia1
1CompletedTreatmentCerebroretinal Vasculopathy, Hereditary / Vasculopathy, Retinal, With Cerebral Leukodystrophy1
Not AvailableRecruitingTreatmentAcute Myeloid Leukemia2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.218 mg/mLALOGPS
logP2.79ALOGPS
logP3.98Chemaxon
logS-3.6ALOGPS
pKa (Strongest Acidic)7.47Chemaxon
pKa (Strongest Basic)8.64Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count15Chemaxon
Hydrogen Donor Count4Chemaxon
Polar Surface Area217.05 Å2Chemaxon
Rotatable Bond Count10Chemaxon
Refractivity203.87 m3·mol-1Chemaxon
Polarizability84.31 Å3Chemaxon
Number of Rings7Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at August 25, 2016 23:13 / Updated at February 21, 2021 18:53